<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>) are being reported with increasing frequency as a complication of ABMT for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>At present there is no method available to predict who is at risk or is destined to develop this nearly universally fatal disorder </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore investigated whether clonal growth of cells is predictive of the development of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In a patient who developed <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 18 months after ABMT, <z:hpo ids='HP_0001417'>X-linked</z:hpo> clonality analysis at the human <z:chebi fb="3" ids="50113">androgen</z:chebi> receptor locus was performed on serial banked samples, and documented transition from polyclonal to clonal hematopoiesis </plain></SENT>
<SENT sid="4" pm="."><plain>Clonal cells could be identified 6 months after transplant (1 year prior to the diagnosis of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>), at a time when there was no morphologic or clinical evidence of disease </plain></SENT>
<SENT sid="5" pm="."><plain>Clonality analysis can be predictive of the development of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> after ABMT and may offer important insights into associated risk factors and strategies to minimize the risk of t-<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
</text></document>